Levitra Pills

When Levitra was launched, they tried to create a tough guy,
macho image for Levitra, as if to say that “even big strong
men experience difficulty getting and staying erect”.
The ads were very “in your face”.

The Levitra marketers used Mike Ditka, a chubby,
aging, macho, football player as a spokesman.  They ran
a promotion whereby you could visit the Levitra website
and sign up to win tickets to the Superbowl (something that
had never been done with a drug before).

However, the macho man campaign didn’t work so well,
so they dumped Ditka.  Then they switched to  a 40-something
year old brunette woman who says something like :
” Do you want to know little secret?  Then she tells
you all about how great Levitra is”.

Now the Levitra advertisements focus on a more subtle effect.  They differentiate it by releasing information regarding its effectiveness in people with diabetes, hypertension and other ailments common to middle aged menfolk.

The Levitra advertisements and propotional materials use a candle as a metaphor for intimacy and passion.

GlaxoSmithKline and Bayer are turning to the National Football League to help promote their new erectile dysfunction drug called Levitra.

Neither GlaxoSmithKline, a London company that has its U.S. headquarters in Philadelphia, nor Bayer of Germany is commenting on the partnership.

Industry sources said the pharmaceutical companies’ sponsorship deal with NFL was for more than $5 million in rights fees. Media spending promoting Levitra during NFL broadcasts is expected to be in the tens of millions of dollars.

In addition, GlaxoSmithKline and Bayer have signed former Chicago Bears head coach Mike Ditka to an endorsement deal, according to sources familiar with the deal.

Levitra, a potential competitor to Pfizer’s Viagra, is still under review by the Food and Drug Administration. The drug is expected to be approved for sale in the United States later this year

Pfizer has also gone the sports marketing route to promote Viagra, which generated sales of about $1.7 billion last year. It has a sponsorship deal with Major League Baseball and an endorsement deal with Rafael Palmeiro of the Texas Rangers. Pfizer also has deals for Viagra with soccer legend Pele, former hockey star Guy Lafleur and NASCAR driver Mark Martin.
Again, no respect

At a forum last week on how to attract people to the area, former Austin, Texas, Mayor Kirk Watson said regional cooperation would help.

For some of that to develop, people have to start thinking regionally, and by one measure, that didn’t happen at the forum.

Although the forum was held at Loews Philadelphia Hotel, slightly more than a mile west of the Delaware River, there was one little proper noun that never gets mentioned in the 90-minute discussion of event.

Neither the five panelists, nor the moderator (lawyer, radio talk-show host and columnist Michael Smerconish), nor the audience members who participated ever said it.

That proper noun? New Jersey.

WebMD posted one of those stories that makes my skin crawl. The formula: use a cute, sexy headline and lead sentence, then follow with weak caveats, leaving the reader with nothing useful at the end.

The story is headlined, “Levitra a Day May Keep the Doctor Away.” It promotes Levitra use with its lead sentences, “Men now have two new reasons to take erection-enhancing drugs every day. Those reasons: The drugs may lower a man’s risk of heart disease and of noncancerous prostate symptoms.” But then it follows with, “This provocative speculation is based on short-term data from a small study.” And it ends with, “But it’s not yet time to start popping those little pills along with your daily vitamins. The study findings… are preliminary.”

How do you justify the headline and the lead with the caveats? And this story was reviewed by a physician? Perhaps the editorial and physician review team need to be reminded of the number of preliminary findings presented at scientific meetings (as this was) that never pan out. And when that happens, journalists like these aren’t around to correct the record.

Chalk it up as a waste of time and space. Come back when you have large-scale, long-term findings to report.